RhumbLine Advisers’s BeOne Medicines Ltd ONC Stock Holding History

RhumbLine Advisers’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Sell	804 -105	-12%	-$30.9K	﹤0.01%	3215
2026 Q1	$270K	Sell	909 -5	-0.5%	-$1.62K	﹤0.01%	2963
2025 Q4	$278K	Sell	914 -23	-2%	-$7.53K	﹤0.01%	3018
2025 Q3	$319K	Sell	937 -199	-18%	-$60.4K	﹤0.01%	2951
2025 Q2	$275K	Sell	1,136 -47	-4%	-$11.5K	﹤0.01%	3046
2025 Q1	$322K	Buy	+1,183	New	+$277K	﹤0.01%	2846
2024 Q4	–	Sell	-1,951	Closed	-$438K	–	4180
2024 Q3	$438K	Hold	1,951	–	–	﹤0.01%	2786
2024 Q2	$278K	Sell	1,951 -150	-7%	-$23.1K	﹤0.01%	3044
2024 Q1	$329K	Sell	2,101 -869	-29%	-$140K	﹤0.01%	2935
2023 Q4	$536K	Sell	2,970 -1,062	-26%	-$192K	﹤0.01%	2620
2023 Q3	$725K	Sell	4,032 -663	-14%	-$131K	﹤0.01%	2383
2023 Q2	$837K	Buy	+4,695	New	+$1.08M	﹤0.01%	2398

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's ONC Position: Q2 2026 in Review

RhumbLine Advisers reduced its BeOne Medicines Ltd (ONC) stake by 12% in Q2 2026, selling an estimated $30.9K and leaving 804 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

RhumbLine Advisers first reported a position in ONC in Q2 2023 and has held it in 12 quarters since. The position peaked at $837K in Q2 2023. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

RhumbLine Advisers held 804 shares of BeOne Medicines Ltd worth $229K as of Q2 2026.
RhumbLine Advisers sold 105 BeOne Medicines Ltd shares in Q2 2026, an estimated $30.9K.
BeOne Medicines Ltd made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3215 holding.
RhumbLine Advisers first reported a position in BeOne Medicines Ltd in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's BeOne Medicines Ltd position peaked at $837K in Q2 2023.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.